Automated Prostate Cancer Annotation Using ML and IHC Staining
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for prostate cancer, such as digital rectal exams, serum PSA, and TRUS-guided biopsies, lack specificity and accuracy, leading to overtreatment and increased morbidity due to uncertainty in disease assessment, especially for men with low-risk disease.
Innovation Solution
The development of machine learning-based systems that analyze whole-slide images of hematoxylin and eosin (H&E) and immunohistochemical (IHC) stained specimens to automate the annotation of prostate cancer, using a predictive model trained on data from radical prostatectomy specimens, which includes staining with a triple-antibody cocktail of HMWCK, p63, and AMACR, to estimate cancerous epithelium distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual annotation of prostatectomy specimens by trained pathologists is used to obtain ground truth data, then accurate cancer detection is achieved, but the process is very time-consuming and laborious
Solution Approach 1:
The patent uses manual pathologist annotations on a subset of specimens to create ground truth labels, then copies this labeling approach to automatically train machine learning models that can annotate all specimens. The trained models replicate the pathologist's detection accuracy without the time cost, enabling scalable annotation while maintaining precision.
Solution Approach 2:
The patent replaces the mechanical process of manual pathologist annotation with an automated machine learning system. The ML models process whole slide images and IHC images computationally, substituting human manual inspection with algorithmic analysis that achieves comparable accuracy while dramatically reducing time and labor requirements.
2Adaptability or versatility
If current diagnostic tests (DRE, PSA, TRUS-guided biopsy) are used for prostate cancer diagnosis, then screening is possible, but specificity is low leading to overtreatment and increased morbidity
Solution Approach 1:
The patent merges multiple data sources including whole slide H&E images, IHC images with triple-antibody cocktails (AMACR, HMWCK, p63), and clinical information into a unified machine learning diagnostic system. This integration of multiple modalities improves diagnostic specificity beyond any single test while maintaining the screening versatility of the workflow.
Solution Approach 2:
The patent changes the diagnostic parameters from traditional clinical measures (PSA levels, biopsy findings) to detailed histopathological image analysis features. By analyzing cellular morphology, staining patterns, and tissue architecture at the microscopic level, the system achieves higher diagnostic specificity while preserving screening capability through automated processing.
3Productivity
If automated machine learning systems are used to analyze whole slide images, then annotation time is reduced and productivity increases, but the complexity of the system increases
Solution Approach 1:
The patent segments the diagnostic workflow into distinct modular components: whole slide image processing module, IHC image processing module, feature extraction module, and prediction module. Each module handles a specific task independently, which manages system complexity while enabling high-throughput automated annotation and maintaining overall productivity.
Data Source
AI summary
Automated, machine learning-based systems are described for the analysis and annotation (i.e., detection or delineation) of prostate cancer (PCa) on histologically-stained pathology slides of prostatectomy specimens. A technical framework is described for automating the annotation of predicted PCa that is based on, for example, automated spatial alignment and colorimetric analysis of both H&E and IHC whole-slide images (WSIs). The WSIs may, as one example, be stained with a particular triple-antibody cocktail against high-molecular weight cytokeratin (HMWCK), p63, and α-methylacyl CoA racemase (AMACR).